A formal evidentiary hearing on the US FDA Center for Drug Evaluation and Research’s proposal to refuse approval of tasimelteon for a jet lag indication will take place virtually Dec. 14-18.
A formal evidentiary hearing on the US FDA Center for Drug Evaluation and Research’s proposal to refuse approval of tasimelteon for a jet lag indication will take place virtually Dec. 14-18.